Recent News

• 03.27.2026 - Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
• 03.01.2026 - Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
• 02.27.2026 - Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
• 02.25.2026 - Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
• 02.25.2026 - Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
• 02.23.2026 - Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
• 02.09.2026 - Celldex to Present at Upcoming Investor Conferences
• 12.09.2025 - Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

Recent Filings

• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.10.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.25.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.25.2026 - EX-99.1 EX-99.1
• 02.25.2026 - 8-K Current report
• 02.10.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.09.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.08.2025 - 4 Statement of changes in beneficial ownership of securities